WOBURN, Mass. -- (BUSINESS WIRE) -- ArQule, Inc. (NASDAQ: ARQL) today announced that it will report its financial results for the second quarter of 2014 on Tuesday, August 5, 2014 at 7:00 a.m. Eastern Time. The Company will hold a conference call at 9:00 a.m. Eastern Time that day to discuss these results.
Conference Call and Webcast
|Date:||Tuesday, August 5, 2014|
|Time:||9:00 a.m., Eastern Time|
Conference Call Numbers
|Domestic (toll free):||(877) 868-1831|
A replay of the conference call will be available beginning two hours after the completion of the call until the end of August 7, 2014 and can be accessed by dialing toll-free 855-859-2056 or 800-585-8367, and outside the U.S. 404-537-3406. The confirmation code for replayed calls is 75401404.
ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company’s targeted, broad-spectrum products and research programs are focused on key biological processes that are central to human cancers. ArQule’s lead product, in Phase 2 and Phase 3 clinical development, is tivantinib (ARQ 197), an oral, selective inhibitor of the c-MET receptor tyrosine kinase. The Company’s pipeline includes: ARQ 092, designed to inhibit the AKT serine/threonine kinase, and ARQ 087, designed to inhibit fibroblast growth factor receptor (FGFR). ArQule’s current discovery efforts, which are based on the ArQule Kinase Inhibitor Platform (AKIP™), are focused on the identification of novel kinase inhibitors that are potent, selective and do not compete with ATP (adenosine triphosphate) for binding to the kinase.